Ensign Peak Advisors, Inc Esperion Therapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $444,721 - $740,314	-133,150 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$4.81 - $11.92 $640,451 - $1.59 Million	133,150 New	133,150 $666,000
Q4 2020 Feb 12, 2021	SELL	$24.2 - $35.76 $528,891 - $781,534	-21,855 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$31.18 - $52.71 $111,936 - $189,228	-3,590 Reduced 14.11%	21,855 $812,000
Q2 2020 Aug 12, 2020	SELL	$30.04 - $51.31 $99,732 - $170,349	-3,320 Reduced 11.54%	25,445 $1.31 Million
Q1 2020 May 11, 2020	SELL	$27.44 - $73.84 $197,211 - $530,688	-7,187 Reduced 19.99%	28,765 $908,000
Q4 2019 Feb 14, 2020	BUY	$35.4 - $59.82 $1.27 Million - $2.15 Million	35,952 New	35,952 $2.14 Million

209

129M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $140M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.